Acumen Pharmaceuticals (ABOS) Projected to Post Earnings on Tuesday

Acumen Pharmaceuticals (NASDAQ:ABOS) will likely be issuing its quarterly earnings data before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter.

Acumen Pharmaceuticals Price Performance

ABOS stock opened at $1.28 on Tuesday. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $76.90 million, a price-to-earnings ratio of -0.93 and a beta of 0.02. The stock’s fifty day simple moving average is $1.46 and its 200-day simple moving average is $2.06. Acumen Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $4.43.

Insider Buying and Selling

In other news, CEO Daniel Joseph Oconnell sold 47,778 shares of the firm’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $1.84, for a total transaction of $87,911.52. Following the completion of the sale, the chief executive officer now directly owns 454,707 shares in the company, valued at $836,660.88. This trade represents a 9.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Matt Zuga sold 28,902 shares of the firm’s stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $1.72, for a total value of $49,711.44. Following the sale, the chief financial officer now owns 231,744 shares of the company’s stock, valued at $398,599.68. This represents a 11.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 131,526 shares of company stock valued at $233,124. 7.10% of the stock is currently owned by company insiders.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.